ERADICATION OF SMALL-CELL LUNG-CANCER CELLS FROM HUMAN BONE-MARROW WITH IMMUNOTOXINS

The potential of autologous bone marrow transplantation to improve the treatment results for patients with small cell lung cancer (SCLC) may be limited by the presence of tumor cells in the graft. We constructe d immunotoxins (ITs) involving 4 monoclonal antibodies and Pseudomonas exotoxin A and investigated the cytotoxicity of the ITs to H-146 SCLC cells in the presence and absence of normal human bone marrow (BM) ce lls. The Pseudomonas exotoxin A conjugate with the MOC-1 antibody, whi ch recognizes an NCAM antigen, was inactive, as tested in a reproducib le soft agar assay. Conjugates involving the monoclonal antibodies MOC -31, NrLu10, and MLuC1 killed about 3.5 log tumor cells at 0.1 mug/ml and >5.0 log at 1 mug/ml. In the absence of BM cells, the combination of the 3 ITs was not superior to each IT used individually. However, w hen H-146 cells were admixed to nucleated BM cells at the ratio of 1:1 0, >5 log tumor cell kill was obtained at a concentration as low as 0. 1 mug/ml of each IT. Survival of normal BM progenitor cells was only m oderately reduced by the IT treatment, even in experiments in which th e 3 ITs were used at 2.5 mug/ml each. Freezing and thawing of the BM, as required in a clinical setting, reduced the colony-forming unit, gr anulocyte-macrophage, and colony-forming unit, granulocyte-erythroid-m acrophage-megakaryocyte, by 30-60% in both treated and untreated cultu res. We conclude that the use of a mixture of the 3 ITs provides a saf e, rapid, and effective method for eradicating SCLC cells from BM used for autologous bone marrow transplantation following high-dose chemot herapy.